<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages>en</availableLanguages>
  <rcn>256615</rcn>
  <id>101082135</id>
  <acronym>NanoDeliveryEnhance</acronym>
  <teaser>Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the...</teaser>
  <objective>Delivery to diseased cells or tissues of therapeutic agents attached or encapsulated in nanoparticles – nanomedicine - presents many benefits, and comprises a rapidly-growing multi-billion-euro market. Lipid-based drug-delivery nano-vehicles, where drugs (not least the recent, very-widely-used, mRNA-based COVID-19 vaccines) are encapsulated in lipid vesicles (liposomes) or lipid nanoparticles, form a substantial part of that market. Nearly all FDA-approved liposomic vehicles are functionalized with poly(ethylene glycol), PEG, moieties, the current gold-standard. These act both to sterically-stabilize the vesicles, and, importantly, increase their blood-retention time and thus their therapeutic efficiency. At the same time, such PEGylation has several drawbacks, including reduced cellular uptake, accumulation of PEG in tissues, and accelerated blood clearance on repeated intravenous dosage due to heightened immune response. We use novel functionalization approaches to overcome these drawbacks.  The present project explores the innovation dimension of our new approach. In particular, is it effective? is it efficient? How widely applicable is it? What is the IPR position for future exploitation of this new strategy? These questions illustrate the high-risk/high-gain nature of this proposal, and are addressed here through several inter-related work packages. Success of our project in demonstrating that our novel approach is significantly superior to the current universally-used PEGylation would not only have a therapeutic advantage for many diseases, but also tap into a large and growing market.</objective>
  <title>Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug delivery</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2023-02-01</startDate>
  <endDate>2024-07-31</endDate>
  <ecSignatureDate>2023-01-26</ecSignatureDate>
  <duration>18</duration>
  <status>CLOSED</status>
  <identifiers>
    <grantDoi>10.3030/101082135</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2023-01-30 14:17:36</sourceUpdateDate>
  <contentCreationDate>2023-09-18 19:24:28</contentCreationDate>
  <contentUpdateDate>2024-09-06 18:33:15</contentUpdateDate>
  <lastUpdateDate>2025-09-19 14:48:55</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <rcn>456025</rcn>
        <id>456025-innovative-nanoparticles-for-drug-delivery</id>
        <title>Innovative nanoparticles for drug delivery</title>
        <contentUpdateDate>2025-05-05 14:18:46</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode>/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode>/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode>/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <organization netEcContribution="150000" totalCost="0" source="corda" order="1" ecContribution="150000" terminated="false" sme="false" type="coordinator">
        <availableLanguages>en</availableLanguages>
        <rcn>1906414</rcn>
        <id>999979306</id>
        <vatNumber>IL520016858</vatNumber>
        <legalName>WEIZMANN INSTITUTE OF SCIENCE</legalName>
        <shortName>WEIZMANN</shortName>
        <address>
          <street>HERZL STREET 234</street>
          <city>Rehovot</city>
          <postalCode>7610001</postalCode>
          <country>IL</country>
          <postBox>26</postBox>
          <url>http://www.weizmann.ac.il</url>
          <geolocation>31.8952532,34.8105616</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode>/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Israel</name>
              <rcn>307661352</rcn>
              <nutsCode>IL</nutsCode>
              <euCode>IL</euCode>
              <isoCode>IL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme type="relatedLegalBasis" source="corda" uniqueProgrammePart="true">
        <availableLanguages>en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode>/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme type="relatedTopic" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>706736</rcn>
        <id>HORIZON_ERC-2022-POC2</id>
        <code>ERC-2022-POC2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS2</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode>/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result type="relatedResult" source="corda">
        <availableLanguages>en</availableLanguages>
        <rcn>1186109</rcn>
        <id>101082135_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - NanoDeliveryEnhance (Novel functionalization of liposomic nano-vehicles for strongly-enhanced drug delivery)</title>
        <description>periodic</description>
        <teaser>The problem we are addressing concerns delivery of drugs via nanoparticles, in particular via liposomes which are sub-micron-sized (ca. 100 nm) vesicles whose membranes are lipid bilayers (similar to the membranes of cells). The delivery of pharmaceutical agents encapsulated...</teaser>
        <sourceUpdateDate>2024-11-04 08:50:14</sourceUpdateDate>
        <contentUpdateDate>2024-11-11 12:06:14</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode>/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode>/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode>/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/37/171</code>
        <title>nanomedicine</title>
        <displayCode>/medical and health sciences/medical biotechnology/nanomedicine</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/159/653/1439</code>
        <title>vaccines</title>
        <displayCode>/medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drugs/vaccines</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/25/69/435</code>
        <title>nano-materials</title>
        <displayCode>/engineering and technology/nanotechnology/nano-materials</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode>/Digital agenda</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode>/Clean air</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode>/Artificial intelligence</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode>/Climate action</displayCode>
      </category>
      <category classification="policyPriorities" type="marker" weight="0">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode>/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages>en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode>/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages>de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode>/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>